iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton’s tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely incurable. Frequent disease relapses occur due to re...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alexander Englisch, Clara Hayn, Susanne Jung, Jonas S. Heitmann, Christopher Hackenbruch, Yacine Maringer, Annika Nelde, Marcel Wacker, Monika Denk, Lisa Zieschang, Christine Kammer, Peter Martus, Helmut R. Salih, Juliane S. Walz
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-08-01
Col·lecció:	Frontiers in Oncology
Matèries:	chronic lymphocytic leukemia peptide vaccine BTK-inhibitor minimal residual disease immunotherapy phase I trial
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1441625/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!